Ascendis Pharma A/S Ordinary Share (ASND) carries a Roarable Rating of C+ (Hold) with 69/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-02, Ascendis Pharma A/S Ordinary Share (NASDAQ: ASND) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $251.27 (-0.68% 1D, market cap $16.67B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, ASND ranks #90 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ASND carries a Roarable C+ (69/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, BBIO (BridgeBio Pharma Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $13.83B) and JAZZ (Jazz Pharmaceuticals plc (Ireland)) posts a D grade (47/100 RQD, P/E N/A, ROIC -4.7%, cap $13.49B). Among the 5-stock peer group, ASND leads on earnings multiple (32.8x) while ASND leads on capital efficiency (9.9% ROIC).
For Ascendis Pharma A/S Ordinary Share (ASND), key quantitative strengths include Big institutional funds and options desks are actively positioning on the bullish side. and Clean SEC annual filing review with no major hidden accounting time-bombs., while primary risk factors center on Broader market pullbacks can still drag down strong stocks in the short run. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9
20D Institutional Volume Accumulation (±5.2% realized swing band)
Cannibal Buyback (-1.24% YoY Shares) & executive Form 4 sales trim 8 pts from alignment
Even with a 69/100 (C+) score, ASND faces multiple-compression risk if 32.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Broader market pullbacks can still drag down strong stocks in the short run.
Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($242.32) or 200D SMA ($238.53) invalidates the momentum regime and cuts Target Base ($263.71) toward Bear Floor ($205.69).
Ascendis Pharma A/S Ordinary Share (ASND) slipped -0.68% to $251.27, trading at 67% of its 52-week range ($188.07 – $282.15). Solid steady margins (10% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.
COPENHAGEN, Denmark, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with
Ascendis Pharma A/S (NASDAQ:ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with hypoparathyroidism treated with TransCon® PTH
GLP-1 drugs are fueling a booming peptide market. Can the new PEPT ETF capitalize on rising demand and expanding medical applications?
Investing.com -- RBC Capital has upgraded the Healthcare sector to Overweight from Market Weight, identifying 11 high-conviction stock ideas across therapeutics and non-therapeutics segments. The upgrade is supported by
Ascendis said the Committee for Medicinal Products for Human Use adopted a positive opinion on Ascendis’s application seeking approval for the drug in achondroplasia.
Ascendis Pharma (ASND) said Friday that the European Medicines Agency's Committee for Medicinal Prod
Final European Commission decision expected during Q4 2026COPENHAGEN, Denmark, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Medicinal Products for Human Use
Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization
BOSTON, October 14, 2026--Liberty All-Star® Growth Fund, Inc. September 2026 Monthly Update
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 13.7% on an annualized basis producing an average annual return of 27.5%. Currently, Ascendis Pharma has a market capitalization of
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +12.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ASND today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ASND. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Ascendis Pharma A/S Ordinary Share (ASND) ranks #90 by composite RQD confidence (69/100, grade C+) and #76 by equity capitalization ($16.67B). Within this direct 5-issuer industry benchmark cohort, ASND leads on earnings valuation at 32.8x trailing P/E, while ASND leads on capital efficiency and profitability with 9.9% ROIC and — gross margin. ASND currently leads its immediate peer cohort in composite quantitative strength at 69/100 (C+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ASND
ACTIVE
Ascendis Pharma A/S Ordinary Share | C+ | 69/100 | 32.8x | — | 9.9% | -0.68% | $16.67B | Benchmark Subject |
| BBIO BridgeBio Pharma Inc. | E | 29/100 | — | 95.8% | -35.0% | +5.97% | $13.83B | /bbio-vs-asnd → |
| JAZZ Jazz Pharmaceuticals plc (Ireland) | D | 47/100 | — | — | -4.7% | +3.92% | $13.49B | /jazz-vs-asnd → |
| SMMT Summit Therapeutics Inc. | D | 47/100 | — | — | -35.0% | -1.05% | $12.96B | /smmt-vs-asnd → |
| VTRS Viatris Inc. | D+ | 57/100 | — | 35.2% | -8.1% | -0.86% | $22.05B | /vtrs-vs-asnd → |
Ascendis Pharma A/S Ordinary Share (ASND) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $16.67B, trailing P/E of 32.8x, forward P/E of 27.6x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of —, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 8/9.
As of 2026-11-02, Ascendis Pharma A/S Ordinary Share (NASDAQ: ASND) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $251.27 (-0.68% 1D, market cap $16.67B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, ASND ranks #90 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ASND carries a Roarable C+ (69/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, BBIO (BridgeBio Pharma Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $13.83B) and JAZZ (Jazz Pharmaceuticals plc (Ireland)) posts a D grade (47/100 RQD, P/E N/A, ROIC -4.7%, cap $13.49B). Among the 5-stock peer group, ASND leads on earnings multiple (32.8x) while ASND leads on capital efficiency (9.9% ROIC).
For Ascendis Pharma A/S Ordinary Share (ASND), key quantitative strengths include Big institutional funds and options desks are actively positioning on the bullish side. and Clean SEC annual filing review with no major hidden accounting time-bombs., while primary risk factors center on Broader market pullbacks can still drag down strong stocks in the short run. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
ASND last traded at $251.27 (-0.68% on volume of 386,802 shares), positioning the stock +3.69% above its 50-day simple moving average ($242.32) and +5.34% above its 200-day simple moving average ($238.53). Across its 52-week range of $188.07 to $282.15, ASND sits at the 67.2% percentile with a 14-day RSI of 66.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.2% ($238.20 to $264.34).
Why ASND Stock slipped -0.68% Today — RQD Quant Desk Flash. Solid steady margins (10% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.
Per the Roarable RQD rating, ASND scores 69 out of 100, a letter grade of C+, with the verdict "Roarable Hold — Upper Neutral / Watch for Breakout." The five pillars are:
What this means for a prospective investor: the strongest pillar is balance-sheet quality, while the cash-generation and insider pillars are the weakest. Per the market data, the stock trades at a trailing P/E of 32.8 and a forward P/E of 27.6, so valuation leaves limited margin for error if earnings disappoint. The 52-week range of $188.07 to $282.15 places the current price of 253 in the upper portion of that band. The C+ grade and "Upper Neutral" verdict suggest a balanced setup in which upside depends on a breakout catalyst that the source data does not identify.
Ascendis Pharma A/S Ordinary Share (ASND) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the profile. Per the market data, operating margin is 13.9% and net margin is 10.9%. Specific products, customers, and revenue model are not available in source data.
Real-time company headlines, analyst actions, and sector developments for Ascendis Pharma A/S Ordinary Share (ASND) • Click "Debate This Headline" to argue it in the Roar Pit below
COPENHAGEN, Denmark, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with
Ascendis Pharma A/S (NASDAQ:ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with hypoparathyroidism treated with TransCon® PTH
GLP-1 drugs are fueling a booming peptide market. Can the new PEPT ETF capitalize on rising demand and expanding medical applications?
Investing.com -- RBC Capital has upgraded the Healthcare sector to Overweight from Market Weight, identifying 11 high-conviction stock ideas across therapeutics and non-therapeutics segments. The upgrade is supported by
Ascendis said the Committee for Medicinal Products for Human Use adopted a positive opinion on Ascendis’s application seeking approval for the drug in achondroplasia.
Ascendis Pharma (ASND) said Friday that the European Medicines Agency's Committee for Medicinal Prod
Final European Commission decision expected during Q4 2026COPENHAGEN, Denmark, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Medicinal Products for Human Use
Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization
Welcome to the ASND (Ascendis Pharma A/S Ordinary Share) Roar Pit. Current RQD Composite is 69/100 (Roarable Hold — Upper Neutral / Watch for Breakout) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (32.8x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on ASND, but look at what you are paying: 32.8x trailing P/E with tightening sector spreads. Unless Ascendis Pharma A/S Ordinary Share expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on ASND, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $253.00 (52-wk range $188.07 - $282.15), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).